Mastering Promotional Material Review28 episodes — not "the gatekeeper," but the work of holding judgment together at the boundary of conflicting interests
A single brochure handed to a physician, a single email, a single line of website copy. The words and numbers written there ── the last person who stops them is the material reviewer. This series draws the map of the work, places it against US, European, and Asian regulatory frameworks, names its mindset and struggles, sits with the solitude of "no-incident" days, dissects the risk worldview between missed flags and over-flagging, unpacks the reviewer's perspectives, points of contention, and reasoning brain, then walks through each material type (product info summaries, advertorials, lecture records, disease awareness, patient materials, comparative claims, case reports), and closes on organizational culture and AI-era review. The reality behind the dismissive label "gatekeeper," across 8 parts and 28 volumes.
Part 1 — The map (kept · already published)
01
Getting to the Essence of Material Review
Not a gatekeeper. Three trusts ── patient decision-making, the trust of healthcare professionals, the survival of the company ── held simultaneously on a single sheet of paper. Read through the four qualities required.
Concept
02
Reading the Five-Layer Net — an introduction to the regulatory matrix
The Pharmaceutical Act, the Advertising Appropriateness Standards, the Sales-Information-Provision Guideline, the JPMA Code, and internal SOPs. How five rules overlap, and where gaps emerge.
ConceptPart 2 — The International Lens: Material Review and Regulation Across Countries
Intl
01
01
United States — Inside FDA OPDP
21 CFR 202 (Prescription Drug Advertising), the Fair Balance doctrine, the OPDP Warning / Untitled Letter system, and the Off-Label case law (Caronia, Vascular Solutions). The contour of the American oversight model.
OverseasIntl
02
02
Europe — EFPIA and the Layered National Regulations
EU Directive 2001/83/EC (Title VIII), the UK ABPI Code of Practice, Germany's HWG (Heilmittelwerbegesetz), France's ANSM "Charte de l'Information promotionnelle" — the European model where an EU-level framework stacks on national law and industry self-regulation.
OverseasIntl
03
03
Asia-Pacific + Japan in Parallel
Korea's KPBMA Fair Trade Code, China's NMPA advertising rules, Australia's Medicines Australia Code of Conduct, and Japan (HanteiG / Advertising Appropriateness Standards) — what is shared and what is country-specific. Where Japan's "five-layer net" sits internationally.
OverseasPart 3 — Mindset and Struggle: Standing at the Boundary of Conflicting Interests
04
Former colleagues — relationships with the marketing team
The person at the same floor of the same building, who one day becomes "the one I review." Memories of projects together, dreams shared over drinks, and the self that says NO today. Putting words to a twisted relationship.
Mindset05
Conflict of interest as part of the oversight function — between revenue and trust
Being a company employee while putting a brake on the company's revenue. Executives stare at quarterly numbers; you try to protect trust half a century out. Conflict of interest is not external — it lives inside you.
Mindset06
Called "the gatekeeper" — the structure of psychological load
The emotional cost a label carries. Isolation at work, work whose meaning is hard to explain even to family, anguish that cannot be posted on social media. Practical handholds for keeping one's mindset intact.
MindsetPart 4 — The Solitude of Immersion: A No-Incident Day Is the Best Day
07
The train driver and the material reviewer — "nothing happens" is the result
The psychology of a train driver who has logged decades without an incident is structurally close to the reviewer who has stopped exaggerated ads and off-label statements. The absence of a metric that recognizes "nothing happening" as outcome.
Solitude08
Achievement submerged in the organization — the cost of going unrecognized
The person who made revenue gets celebrated. The person who prevented an incident is treated as if they were not there. How the malfunction of recognition accumulates in mental health — the "invisible burnout" of veteran reviewers.
Solitude09
The architecture of fighting alone — you stop it alone, you're blamed alone
When you stop something, it's your name on it. When something goes wrong, you bear responsibility. When nothing goes wrong, no gratitude follows. Dissecting the structure of being placed at the "organizational rearguard" alone, from an organizational-theory perspective.
SolitudePart 5 — The Risk Worldview: Between 100% and Over-Flagging
10
The fear of a missed flag — the nights of "I could have stopped that"
Violations noticed after distribution, inquiries from patients, queries from the PMDA. The weight of the night you realize "I missed that one sentence." A missed flag costs more than business loss — it costs an inner trial.
Risk11
The trap of over-flagging — measuring the burden on the business side
"Just in case" flags, accumulated, stop the field from moving. Marketing and MR lose trust, and stop consulting you — the "isolation" that follows. The structure by which risk avoidance generates new risk.
Risk12
The scales of judgment — designing appropriateness and risk tolerance
Where to operate, on the line between missed flags and over-flagging. How an organization decides "this far is acceptable," and how it changes that line over time. Includes the craft of dialogue with executives.
RiskPart 6 — Perspective, Issue, Brain: The Architecture of Reasoning
03
Efficacy claims within the approved scope (repositioned as the anchor of Part 5)
The boundaries of the package insert, expressions that cross them, the line between implication and statement. The traps of "almost" and "feels like" — the first concrete example for learning the reasoning structure.
Brain13
Perspective, point of contention, field of view — reading one material with three layers of vision
"Perspective" is where you stand. "Point of contention" is the question. "Field of view" is what you capture. The skill of reading one piece of material while switching among the lenses of the patient, physician, PMDA, MR, and executive.
Brain14
A taxonomy of statutes, regulations, and industry rules — where each norm comes from
Pharmaceutical Act (statute), enforcement orders and rules, public notices, guidelines, the JPMA Code, internal SOPs ── classifying the hierarchy and scope of norms, systematizing "where does this come from, and how far does it bind."
Brain15
Reasoning and logical development — how do you derive "this is a violation"
Gather information → apply the norm → build the logic → reach the conclusion. Make the chain of reasoning that runs inside a reviewer's head structurally visible, and transmit it as a reproducible technique of thought.
BrainPart 7 — Review Points by Material Type (per JPMA Creation Guidelines)
16
Product Information Summary (incl. Specific PI Summary)
The most important material directed at healthcare professionals. The roles of the comprehensive PI summary vs. the specific (item-level) PI summary, alignment with the package insert, parity of efficacy / safety presentation, citation scope, visual composition — applying Part 6's reasoning over the JPMA Creation Guidelines.
Practice17
Advertorials — the line in medical journal placements
Advertising laid out in the editorial style of a medical journal. The distinction between "article" and "ad," authorial independence disclosure, citation of Substantial Evidence, and disclosure of editorial involvement. How review can close the reader's risk of mistaking the piece for editorial content.
Practice18
Roundtable materials — bundling multiple physicians' statements
The tension between the convening company's intent and the physicians' independence. Editorial rights over statements, citation context, and how to avoid a structure that simply assembles "praise" for a specific product.
Practice19
Lecture / Symposium record collections — putting a speaker's words into print
The craft of making booklets from your-company-hosted or co-hosted lectures. How to handle a speaker's Off-Label remarks, the limits of editorial intervention, and the structural shift that occurs the moment something becomes printed text: it becomes "advertising."
Practice20
Disease awareness materials — the issue of "product-name-less" advertising
The boundary between "helping people notice a disease" and steering toward a specific in-house product. Read in parallel with the U.S. DTC "Help-Seeking Ad." The review craft for ensuring that disease awareness does not become covert advertising.
Practice21
Materials for patients currently taking the company's drug
Materials delivered directly to patients already on therapy. Supplementing dispensing guidance, adverse-event awareness, prompting consultation with healthcare professionals — designed in language and visuals matching the patient's comprehension, without inducing excessive reassurance (i.e., risk minimization).
Practice22
Comparison of own drug vs. competitor drug
The requirements for claiming superiority of your own product over a competitor's through comparison. The limits of indirect comparison, identity of indication / dose / patient population, and the comparison-expression craft set out in the JPMA Creation Guidelines.
Practice23
Case reports — what can n=1 actually say
The generalization traps lurking in single-case or small-case introductions. The distinction between a "representative case" and an "exceptionally responsive case," fair presentation of adverse events and treatment response, patient privacy, and the independence of the authoring physician.
PracticePart 8 — Culture and the Next Generation (developing the earlier series + AI)
24
After NO, always offer YES — the craft of counter-proposal
Can you follow "this won't pass" with "if we do this, it will"? The review that ends in NO, vs. the review that walks alongside toward YES.
Culture25
Turning review into a culture — of organizations and people
Not the strength of one reviewer, but the design of a culture that can stop a material. Redesigning the relationships among sales reps, marketing, and review. Includes the craft of upward dialogue with executives.
Culture26
Material review in the AI era — the violence of speed and the responsibility of judgment
In an era when generative AI mass-produces materials, can review speed keep up? In the structure of "AI drafts the material, AI reviews it," who bears the final responsibility? The series closes with the craft we must pass to the next generation.
CultureRevised June 7, 2026 — the series has been expanded to an 8-part / 29-volume structure (Vol 01–26 + Overseas 01–03). Vols 1, 2 + Vol 3 (efficacy claims) + Overseas 01 (USA) are already available. The remaining 25 volumes will be released in turn.
← Back to Ad Regulations